VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: An in silico model

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 6, 2010, Pages

  Wu, Florence T H ^a   Stefanini, Marianne O ^a   Mac Gabhann, Feilim ^b   Kontos, Christopher D ^c   Annex, Brian H ^d   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Computational model; Mathematical model; Molecular systems biology; Therapeutic angiogenesis

Indexed keywords

NEUROPILIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTERY DISEASE; ARTICLE; BLOOD; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; PRIORITY JOURNAL;

CAPILLARIES; HUMANS; LEG; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; PERIPHERAL VASCULAR DISEASES; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77952651450     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00365.2009     Document Type: Article

References (83)

1. Askew CD, Green S, Walker PJ, Kerr GK, Green AA, Williams AD, Febbraio MA. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J Vasc Surg 41: 802-807, 2005. (Pubitemid 40693802)
2. Aukland K, Nicolaysen G. Interstitial fluid volume: local regulatory mechanisms. Physiol Rev 61: 556-643, 1981.
3. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, MartinyBaron G. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272: 10382-10388, 1997. (Pubitemid 27181038)
4. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28: 1737-1743, 1989. (Pubitemid 19072047)
5. Baum O, Djonov V, Ganster M, Widmer M, Baumgartner I. Arteriolization of capillaries and FGF-2 upregulation in skeletal muscles of patients with chronic peripheral arterial disease. Microcirculation 12: 527-537, 2005. (Pubitemid 41341794)
6. Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci (Lond) 100: 567-575, 2001.
7. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GYH. Vascular endothelial growth factor and its receptor, Flt-l, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci (Lond) 102: 187-194, 2002. (Pubitemid 34185046)
8. Borisov AB, Carlson BM. Cell death in denervated skeletal muscle is distinct from classical apoptosis. Anat Rec 258: 305-318, 2000. (Pubitemid 30146013)
9. Brown MD, Kelsall CJ, Milkiewicz M, Anderson S, Hudlicka O. A new model of peripheral arterial disease: sustained impairment of nutritive microcirculation and its recovery by chronic electrical stimulation. Microcirculation 12: 373-381, 2005. (Pubitemid 40872929)
10. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281: 3604-3613, 2006. (Pubitemid 43845978)
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
12. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63: 601-615, 2006.
13. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, Mooney DJ. Integrated approach to designing growth factor delivery systems. FASEB J 21: 3896-3903, 2007. (Pubitemid 350232347)
14. Cisek PL, Eze AR, Comerota AJ, Kerr R, Brake B, Kelly P. Microcirculatory compensation to progressive atherosclerotic disease. Ann Vasc Surg 11: 49-53, 1997. (Pubitemid 27164372)
15. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg 28: 9-23, 2004. (Pubitemid 38950133)
16. Damon DH. Sympathetic innervation promotes vascular smooth muscle differentiation. Am J Physiol Heart Circ Physiol 288: H2785-H2791, 2005.
17. de Graaff JC, Ubbink DT, van der Spruit JA, Lagarde SM, Jacobs MJHM. Influence of peripheral arterial disease on capillary pressure in the foot. J Vasc Surg 38: 1067-1074, 2003. (Pubitemid 37409645)
18. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47: 149-161, 2003. (Pubitemid 37279152)
19. Duerschmied D, Olson L, Olschewski M, Rossknecht A, Freund G, Bode C, Hehrlein C. Contrast ultrasound perfusion imaging of lower extremities in peripheral arterial disease: a novel diagnostic method. Eur Heart J 27: 310-315, 2006. (Pubitemid 43100026)
20. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2: 315-326, 2004. (Pubitemid 39025294)
21. Elliott MA, Walter GA, Gulish H, Sadi AS, Lawson DD, Jaffe W, Insko EK, Leigh JS, Vandenborne K. Volumetric measurement of human calf muscle from magnetic resonance imaging. MAGMA 5: 93-98, 1997. (Pubitemid 27328551)
22. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
23. Filion RJ, Popel AS. Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. Am J Physiol Heart Circ Physiol 288: H263-H279, 2005.
24. Filion RJ, Popel AS. A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Ann Biomed Eng 32: 645-663, 2004.
25. Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 52: 387-393, 2008.
26. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 275: 26690-26695, 2000.
27. Gavin TP, Ruster RS, Carrithers JA, Zwetsloot KA, Kraus RM, Evans CA, Knapp DJ, Drew JL, McCartney JS, Garry JP, Hickner RC. No difference in the skeletal muscle angiogenic response to aerobic exercise training between young and aged men. J Physiol 585: 231-239, 2007. (Pubitemid 350131115)
28. Gustafsson T, Ameln H, Fischer H, Sundberg CJ, Timmons JA, Jansson E. VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise. J Appl Physiol 98: 2137-2146, 2005. (Pubitemid 40726908)
29. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101: 948-956, 2007. (Pubitemid 350287182)
30. Hiatt WR. Drug therapy - medical treatment of peripheral arterial disease and claudication. N Engl J Med 344: 1608-1621, 2001. (Pubitemid 32479915)
31. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol 81: 780-788, 1996. (Pubitemid 26303231)
32. Hoffner L, Nielsen JJ, Langberg H, Hellsten Y. Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium. J Physiol 550: 217-225, 2003. (Pubitemid 36869282)
33. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80: 443-454, 2000. (Pubitemid 30226626)
34. Hornig C, Weich HA. Soluble VEGF receptors. Angiogenesis 3: 33-39, 1999.
35. Isbell DC, Epstein FH, Zhong X, DiMaria JM, Berr SS, Meyer CH, Rogers WJ, Harthun NL, Hagspiel KD, Weltman A, Kramer CM. Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 25: 1013-1020, 2007. (Pubitemid 46697572)
36. Ji JW, Mac Gabhann F, Popel AS. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Am J Physiol Heart Circ Physiol 293: H3740-H3749, 2007. (Pubitemid 350230922)
37. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996. (Pubitemid 26331903)
38. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 21: 6188-6193, 1982.
39. Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clin Sci 101: 305-311, 2001. (Pubitemid 32835528)
40. Levick JR. Flow through interstitium and other fibrous matrices. Q J Exp Physiol 72: 409-437, 1987.
41. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 56: 656-665, 2007. (Pubitemid 46348460)
42. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches. PLoS Comput Biol 2: e180, 2006.
43. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 15: 715-738, 2008.
44. Mac Gabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol 292: H459-H474, 2007. (Pubitemid 46115924)
45. Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond) 104: 397-404, 2003.
46. Makitie J. Skeletal muscle capillaries in intermittent claudication. Arch Pathol Lab Med 101: 500-503, 1977. (Pubitemid 8177405)
47. Marko SB, Damon DH. VEGF promotes vascular sympathetic innervation. Am J Physiol Heart Circ Physiol 294: H2646-H2652, 2008.
48. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 47: 921-929, 2006. (Pubitemid 43312751)
49. McDermott MM, Lloyd-Jones DM. The role of biomarkers and genetics in peripheral arterial disease. J Am Coll Cardiol 54: 1228-1237, 2009.
50. McGuigan MRM, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, Kraemer WJ. Muscle fiber characteristics in patients with peripheral arterial disease. Med Sci Sports Exerc 33: 2016-2021, 2001. (Pubitemid 33126692)
51. McGuigan MRM, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, Kraemer WJ. Resistance training in patients with peripheral arterial disease: effects on myosin isoforms, fiber type distribution, and capillary supply to skeletal muscle. J Gerontol Ser A-Biol Sci Med Sci 56: B302-B310, 2001.
52. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 18: 185-192, 1998. (Pubitemid 28277594)
53. Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 3: 225-233, 2001.
54. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220: 112-121, 2001. (Pubitemid 32107812)
55. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, Rutherford RB. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 26: 81-157, 2007. (Pubitemid 47034276)
56. Ohira Y, Yoshinaga T, Ohara M, Nonaka I, Yoshioka T, Yamashita-Goto K, Shenkman BS, Kozlovskaya IB, Roy RR, Edgerton VR. Myonuclear domain and myosin phenotype in human soleus after bed rest with or without loading. J Appl Physiol 87: 1776-1785, 1999.
57. Olszewski W, Engeset A, Jaeger PM, Sokolowski J, Theodorsen L. Flow and composition of leg lymph in normal men during venous stasis, muscular activity and local hyperthermia. Acta Physiol Scand 99: 149-155, 1977. (Pubitemid 8054982)
58. Osada-Oka M, Ikeda T, Imaoka S, Akiba S, Sato T. VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells. J Atheroscler Thromb 15: 26-33, 2008.
59. Ouriel K. Peripheral arterial disease. Lancet 358: 1257-1264, 2001.
60. Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 11: 409-413, 1996. (Pubitemid 26192844)
61. Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag 28: 14-31, 2009.
62. Qutub AA, Popel AS. A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. J Cell Sci 119: 3467-3480, 2006.
63. Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR. Chronic changes in skeletal-muscle histology and function in peripheral arterial disease. Circulation 87: 413-421, 1993.
64. Rohrbach DH, Wagner CW, Star VL, Martin GR, Brown KS, Yoon JW. Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin-induced diabetic mice. J Biol Chem 258: 11672-11677, 1983.
65. Schiekofer S, Galasso G, Sato K, Kraus BJ, Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 25: 1603-1609, 2005. (Pubitemid 41098928)
66. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102: 1566-1574, 2008.
67. Semenza GL. Regulation of vascularization by hypoxia-inducible factor 1. Ann N Y Acad Sci 1177: 2-8, 2009.
68. Shimazaki M, Matsuki T, Yamauchi K, Iwata M, Takahashi H, Genda S, Ohata J, Nakamura Y, Inaba Y, Yokouchi S, Kikuiri T, Ashie T. Assessment of lower limb ischemia with measurement of skin perfusion pressure in patients on hemodialysis. Ther Apher Dial 11: 196-201, 2007. (Pubitemid 46716160)
69. Siperstein MD, Unger RH, Madison LL. Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest 47: 1973-1999, 1968.
70. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol 2: 77, 2008.
71. Stoyioglou A, Jaff MR. Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol 15: 1197-1207, 2004. (Pubitemid 39487849)
72. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109: 227-241, 2005. (Pubitemid 41337127)
73. Vainas T, Stassen FR, de Graaf R, Twiss EL, Herngreen SB, Welten RJ, van den Akker LH, van Dieijen-Visser MP, Bruggeman CA, Kitslaar PJ. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 42: 243-251, 2005. (Pubitemid 41139229)
74. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 282: 37585-37596, 2007.
75. Vracko R. Skeletal muscle capillaries in nondiabetics. A quantitative analysis. Circulation 41: 271-283, 1970.
76. Ward SR, Lieber RL. Density and hydration of fresh and fixed human skeletal muscle. J Biomech 38: 2317-2320, 2005.
77. Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries MJ, Sobel M. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 99: 853-860, 2006. (Pubitemid 44556384)
78. Williamson JR, Hoffmann PL, Kohrt WM, Spina RJ, Coggan AR, Holloszy O. Endurance exercise training decreases capillary basement membrane width in older nondiabetic and diabetic adults. J Appl Physiol 80: 747-753, 1996.
79. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role & therapeutic use. J Cell Mol Med 14: 528-552, 2010.
80. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics 38: 29-41, 2009.
81. Wu FT, Stefanini MO, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One 4: e5108, 2009.
82. Yamazaki Y, Nakano Y, Imamura T, Morita T. Augmentation of vascular permeability of VEGF is enhanced by KDR-binding proteins. Biochem Biophys Res Commun 355: 693-699, 2007. (Pubitemid 46330208)
83. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49: 1015-1026, 2007. (Pubitemid 46349500)